Synopsis A clinical study demonstrates that once-weekly dulaglutide, compared with titrated daily insulin glargine, both combined with insulin lispro, attenuated the decline in eGFR in patients with T2DM and moderate-to-severe chronic kidney disease (CKD). These benefits were achieved while lowering HbA1c to a similar extent to insulin glargine, but with weight loss and a substantially lower rate of hypoglycaemia. This week's ' MED FACT ' discusses a clinical trial from Lancet Diabetes & Endocrinology , “ Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial ”.
June 2018. Authors : Tuttle KR; Lakshmanan MC; Rayner B; Busch RS; Zimmermann AG; Woodward DB, Botros FT. Key Takeaways Dulaglutide is effective to achieve glycaemic control in patients with moderate-to-severe…
